• Wednesday, May 25th 2016 at 15:00 - 16:00 UK (Other timezones)
  • General participation info   |   Participate online   |   + Phone in United States: +1 (571) 317-3129 Australia (toll-free): 1 800 193 385 Australia: +61 2 8355 1020 Austria (toll-free): 0 800 202148 Belgium (toll-free): 0 800 78884 Canada (toll-free): 1 888 455 1389 Denmark (toll-free): 8090 1924 France (toll-free): 0 805 541 047 Germany (toll-free): 0 800 184 4222 Israel (toll-free): 1 809 454 830 Italy (toll-free): 800 793887 Netherlands (toll-free): 0 800 020 0182 New Zealand (toll-free): 0 800 47 0011 Norway (toll-free): 800 69 046 Poland (toll-free): 00 800 1213979 Portugal (toll-free): 800 819 575 Spain (toll-free): 800 900 582 Switzerland (toll-free): 0 800 740 393 United Kingdom (toll-free): 0 800 169 0432 United States (toll-free): 1 877 309 2073 Access Code: 731-636-357 Audio PIN: Shown after joining the meeting Meeting ID: 731-636-357

The last few years has witnessed an explosion of the number and types of biological measures that can -and are- measured quantitatively and non-invasively in clinical populations. In most areas of medicine, this has led to biological tests that have revolutionised diagnosis and treatment allocation. However, this is not the case in psychiatry, which is now virtually the last area of medicine where diseases are still diagnosed based on symptoms and biological tests to assist treatment allocation remain to be developed. In this talk, I will present work from our group that aims to use neuroimaging data derived from large population-based cohorts as biomarkers that predict disease state and outcome in psychiatric disorders. I will also discuss recent initiatives for mapping the hetereogeneity underlying psychiatric disorders on the basis of mappings between biology and the behaviours that depend on that biology. This provides a method to understand variation in clinical cohorts at the level of individual participants, so that each individual subject can be placed within the population range and disease mechanisms can be studied independently from the diagnostic labels. The hope is that this will move the field beyond simple case-control comparisons and will ultimately lead to biologically based tests that improve outcomes for patients.

Marquand Andre-bfe80c92







Andre Marquand is Assistant Professor at the Donders Institute, working in the Statistical Imaging Neuroscience group. He has a particular focus on machine learning techniques that aim to learn to detect patterns of statistical regularity in empirical data. These methods hold significant promise for decoding cognitive states and predicting clinically relevant variables in health and disease.

Video of the session:

Andre Marquand – From big data to precision medicine in psychiatry

Leave a Reply